Entity > Corporation > AU > Melbourne Victoria > Immutep
About Immutep
Industry: Business & Industrial > Pharmaceuticals & Biotech
More information about Immutep
| Company Attribute | Value |
| Address | StreetAddress: 33 Australia Sq L 264, AddressLocality: Sydney, AddressRegion: New South Wales, PostalCode: 2000, AddressCountry: Australia |
| Founding Date | 2001 |
| Name | Immutep |
| Number Of Employees | 35 |
| Revenue | $4,252,000 USD |
| Ticker Symbol | NASDAQ: IMMP |
| Url | immutep |
| Wikipedia | wikipedia |
| Wikidata | wikidata |
Immutep
Melbourne, AU
26 Apr 2024
Immutep
All
News
Images
Maps
Videos
More
Page: 1
Desktop | Laptop Devices
https://www.immutep.com/
Immutep is a leading biotechnology company focused on developing effective autoimmune and cancer immunotherapy treatments such as Lag-3.
Rich Sitelinks
People Also Ask
News
https://finance.yahoo.com › quote › IMMP
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases.
https://www.asx.com.au › markets › company › IMM
View today's IMM share price, options, bonds, hybrids and warrants. View announcements, advanced pricing charts, trading status, fundamentals, ...
https://en.wikipedia.org › wiki › Immutep
Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control ...
https://twitter.com/immutep?lang=en
A late-stage clinical biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease. (ASX: IMM, NASDAQ: IMMP)
https://www.marketindex.com.au › asx › imm
Immutep Limited (IMM, Prima BioMed Ltd) is a globally active biotechnology company that is a leader in the development of LAG-3 immunotherapeutic products ...
Related Searches
immutep news today
immutep sas
immutep buyout
Knowledge Panel
Immutep (Biotechnology company)
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
-
Stock price : IMM (ASX) $0.45 0.00 (0.00%)24 Apr, 4:10 pm AEST - Disclaimer
-
CEO : Marc Voigt (July 2014–)
-
Headquarters : New South Wales
-
Founded : 2001
| Entity Home | Kalicube Pro Entity Page |